Nearmedic
Moscow
About Nearmedic
NEARMEDIC will base its pharmaceutical production on Kagocel®, an antiviral drug available over the counter. Construction of the new GMP-tailored manufacturing facility will enable NEARMEDIC to remove Kagocel production from a rented facility and greatly expand manufacturing operations to further strengthen its Russian and the CIS market positions. Kagocel is a compound of an active plant-based gossypol molecule with a nanosized polymer carrier. The joining of this small molecule to a highmolecular-weight polymer-carrier prevents rapid metabolism of the active ingredient in the organism, prolonging the drug’s pharmacological activity and avoiding toxicity. Therein lies its uniqueness. Kagocel elicits the formation of alpha- beta- and gamma-interferons in the human organism. The interferons have highly antiviral activity, effective in treatment and prevention of flu and other acute respiratory infections and in treatment of herpes infections.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Last round: Series Unknown (Oct 2011)
- Website: nearmedic.ruen
Industries & Categories
Biopharma, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nearmedic-1374431 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.